Craig, Z., Swain, J., Batman, E., Wadsley, J., Reed, N., Faluyi, O., Cave, J., Sharma, R., Chau, I., Wall, L., Lamarca, A., Hubner, R., Mansoor, W., Sarker, D., Meyer, T., Cairns, D. A., Howard, H., Valle, J. W., & McNamara, M. G. (2020). nET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). BMJ open, 10(2), . http://access.bl.uk/ark:/81055/vdc_100137791913.0x000008